Lineage Cell Therapeutics (LCTX) Misses Q3 EPS by 1c

Lineage Cell Therapeutics (NYSE: LCTX) reported Q3 EPS of ($0.04), $0.01 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $3 million versus the consensus estimate of $3.82 million.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• BofA lists top 5 themes driving next $1tn in incremental semi sales
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth